MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer

Published in Gut (IF: 24.5), 2024

This study characterizes the role of MED12 loss in activating endogenous retroelements, which sensitizes pancreatic ductal adenocarcinoma (PDAC) to immune checkpoint blockade. Using integrative multi-omics analysis, we demonstrate that MED12 deficiency rewires the tumor immune microenvironment, offering a potential biomarker for immunotherapy response in pancreatic cancer. Published as co-first author in *Gut* (2024).

Recommended citation: Tang Y*, Tang S*, Yang W, et al. MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer. Gut. Published Online First: 31 August 2024. doi:10.1136/gutjnl-2024-332350 (*co-first author)
Download Paper